DK3601265T3 - Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol - Google Patents

Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol Download PDF

Info

Publication number
DK3601265T3
DK3601265T3 DK18714751.7T DK18714751T DK3601265T3 DK 3601265 T3 DK3601265 T3 DK 3601265T3 DK 18714751 T DK18714751 T DK 18714751T DK 3601265 T3 DK3601265 T3 DK 3601265T3
Authority
DK
Denmark
Prior art keywords
ylquinazolin
pyridazin
chlor
morpholin
fluor
Prior art date
Application number
DK18714751.7T
Other languages
English (en)
Inventor
Michael Lange
Clemens Kuehn
Thomas Fuchss
David Maillard
Marcel Breuning
Marco Poma
Edoardo Burini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK3601265T3 publication Critical patent/DK3601265T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054Use of anti-solvent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18714751.7T 2017-03-30 2018-03-28 Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol DK3601265T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163826 2017-03-30
PCT/EP2018/057875 WO2018178133A1 (en) 2017-03-30 2018-03-28 Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol

Publications (1)

Publication Number Publication Date
DK3601265T3 true DK3601265T3 (da) 2023-09-18

Family

ID=58461171

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18714751.7T DK3601265T3 (da) 2017-03-30 2018-03-28 Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol

Country Status (16)

Country Link
US (1) US11053233B2 (da)
EP (1) EP3601265B1 (da)
JP (1) JP7365904B2 (da)
KR (1) KR20190136037A (da)
CN (1) CN110446705B (da)
AU (1) AU2018246257B2 (da)
CA (1) CA3058285C (da)
DK (1) DK3601265T3 (da)
ES (1) ES2956036T3 (da)
IL (1) IL269667B2 (da)
MX (1) MX2019011649A (da)
RU (1) RU2019133577A (da)
SG (1) SG11201909059XA (da)
TW (1) TWI781161B (da)
WO (1) WO2018178133A1 (da)
ZA (1) ZA201907144B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP3601271B1 (en) * 2017-03-30 2022-06-08 Merck Patent GmbH Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
KR20220027183A (ko) * 2019-06-27 2022-03-07 메드샤인 디스커버리 아이엔씨. Dna-pk 억제제로서의 퀴놀린 및 시놀린 유도체
CN116670128A (zh) * 2020-12-28 2023-08-29 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (da) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
WO2008099887A1 (ja) * 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. メチル n-[3-(6,7-ジメトキシ-2-メチルアミノキナゾリン-4-イル)フェニル]テレフタラミックアシッドの結晶、非晶質体または塩
CN101939009B (zh) * 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
IT1404157B1 (it) * 2010-12-30 2013-11-15 Nano Active Film S R L Forma cristallina nanoporosa disordinata di polistirene sindiotattico, suo processo di preparazione e articoli comprendenti la stessa.
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
US20140377258A1 (en) * 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
US10905146B2 (en) * 2013-07-12 2021-02-02 The Coca-Cola Company Compositions for improving rebaudioside M solubility
EP3307722B1 (en) 2015-06-12 2021-08-04 GB006, Inc. Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Also Published As

Publication number Publication date
AU2018246257B2 (en) 2022-05-12
AU2018246257A8 (en) 2019-11-28
IL269667A (en) 2019-11-28
CN110446705B (zh) 2023-04-14
ES2956036T3 (es) 2023-12-12
IL269667B1 (en) 2024-05-01
CA3058285A1 (en) 2018-10-04
TWI781161B (zh) 2022-10-21
JP7365904B2 (ja) 2023-10-20
ZA201907144B (en) 2023-10-25
RU2019133577A3 (da) 2021-07-30
CN110446705A (zh) 2019-11-12
US11053233B2 (en) 2021-07-06
MX2019011649A (es) 2019-12-19
EP3601265A1 (en) 2020-02-05
TW201900634A (zh) 2019-01-01
JP2020512362A (ja) 2020-04-23
RU2019133577A (ru) 2021-04-30
SG11201909059XA (en) 2019-10-30
US20200123144A1 (en) 2020-04-23
EP3601265B1 (en) 2023-06-21
AU2018246257A1 (en) 2019-11-14
KR20190136037A (ko) 2019-12-09
CA3058285C (en) 2024-02-06
IL269667B2 (en) 2024-09-01
WO2018178133A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3371171T3 (da) Inhibitorer af RET
DK3377059T3 (da) Hæmmere af cxcr2
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3433234T3 (da) Allosteriske modulatorer af nicotinacetylcholinreceptorer
DK3448846T3 (da) Syntese af indazoler
DK3088456T3 (da) Skaktdæksel af termohærdet polymer
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3317394T3 (da) Anordning til opformering af mikrovæv
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3601265T3 (da) Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3457851T3 (da) Derivater af sobetirom
DK3448849T3 (da) Syntese af indazoler
DK3318115T3 (da) Maskine til behandling af svinegylle
DK3692039T3 (da) Enantiomerer af substituerede thiazoler som antivirale forbindelser
DK3649781T3 (da) Forbedring af tvungen grænseopdeling
DK3697418T3 (da) Forbedrede formuleringer af bromocriptin
DK3458467T3 (da) Fremgangsmåde til 6,7-alfa-epoxidering af steroid-4,6-diener
DK3638293T5 (da) Sammensætninger til behandling af cancer